详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma

119| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China [b]Department of Surgery & The Pancreatic Cancer Precision Medicine Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA [c]Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, & Pancreas Institute of Nanjing Medical University, Nanjing, PR China [d]Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, PR China [e]Department of Biliary Surgery, West China Hospital of Sichuan University, Sichuan, PR China [f]Liver Cancer Institute, Zhongshan Hospital, & Key Laboratory of Carcinogenesis & Cancer Invasion (Ministry of Education), Fudan University, Shanghai, PR China [g]Department of General Surgery, The Second Affiliated Hospital of Soochow University, Jiangsu, PR China

出处：

DOI：

ISSN：

关键词： AJCC pancreatic ductal adenocarcinoma prognosis risk survival

摘要：

Aim: To reassess the prognostic performance of the American Joint Committee on Cancer (AJCC) 8th edition for pancreatic ductal adenocarcinoma (PDAC) and optimize the categorization of PDAC staging. Patients & methods: A total of 11,858 patients with resected PDAC from the Surveillance, Epidemiology and End Results database were retrospectively enrolled by sequential analyses. Results: There was no statistical significance between stage IIA and IIB tumors with hazard ratios of 2.065 and 2.184 (p = 0.620) for stages IIA and IIB, respectively. With the proposed modification, there was a significant difference between the hazard ratios of stages IIIA and IIIB which were 2.481 and 2.715, respectively (p = 0.009). The C-index of modified system was 0.609, slightly higher than AJCC 8th staging system 0.604. Conclusion: We proposed a modified eighth edition of the AJCC staging system by combining stage IIA with IIB and further subclassifying stage III patients in order to lead to better discriminative power. © 2019 Future Medicine Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2019]版：

Q3 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3 最新[2023版] 2.9 最新五年平均 2.66 出版当年[2019版] 2.379 出版当年五年平均 2.279 出版前一年[2018版] 3.404 出版后一年[2020版]

第一作者：

第一作者机构： [a]Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China [b]Department of Surgery & The Pancreatic Cancer Precision Medicine Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma

文献详情

相关文献